Bamco Inc. NY boosted its position in shares of Danaher Co. (NYSE:DHR - Free Report) by 20.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 72,419 shares of the conglomerate's stock after purchasing an additional 12,500 shares during the period. Bamco Inc. NY's holdings in Danaher were worth $20,134,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also modified their holdings of DHR. Paloma Partners Management Co lifted its stake in shares of Danaher by 562.8% in the 3rd quarter. Paloma Partners Management Co now owns 38,098 shares of the conglomerate's stock valued at $10,592,000 after purchasing an additional 32,350 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Danaher in the third quarter valued at approximately $7,484,000. FSA Wealth Management LLC bought a new stake in shares of Danaher during the 3rd quarter worth $50,000. B&L Asset Management LLC bought a new position in Danaher in the 3rd quarter worth $425,000. Finally, Erste Asset Management GmbH acquired a new position in Danaher during the 3rd quarter worth $5,988,000. Institutional investors and hedge funds own 79.05% of the company's stock.
Analyst Ratings Changes
DHR has been the topic of a number of recent analyst reports. StockNews.com upgraded Danaher from a "hold" rating to a "buy" rating in a research note on Wednesday, November 27th. Robert W. Baird reduced their price objective on Danaher from $278.00 to $277.00 and set an "outperform" rating for the company in a research report on Wednesday, October 23rd. KeyCorp boosted their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 23rd. Wolfe Research raised shares of Danaher from a "peer perform" rating to an "outperform" rating and set a $285.00 price target for the company in a report on Thursday, October 31st. Finally, Wells Fargo & Company began coverage on Danaher in a research note on Tuesday, August 27th. They set an "equal weight" rating and a $280.00 price target on the stock. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $287.16.
Read Our Latest Stock Analysis on Danaher
Danaher Stock Down 0.4 %
DHR stock traded down $0.96 during mid-day trading on Tuesday, hitting $240.33. 944,670 shares of the company were exchanged, compared to its average volume of 2,752,085. The firm's 50 day simple moving average is $254.59 and its 200 day simple moving average is $259.41. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. Danaher Co. has a 1-year low of $215.68 and a 1-year high of $281.70. The firm has a market cap of $173.59 billion, a P/E ratio of 46.04, a P/E/G ratio of 4.41 and a beta of 0.83.
Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts' consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company's quarterly revenue was up 3.1% compared to the same quarter last year. During the same period in the previous year, the company posted $2.02 earnings per share. On average, sell-side analysts predict that Danaher Co. will post 7.5 EPS for the current fiscal year.
Danaher Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were issued a dividend of $0.27 per share. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.45%. Danaher's payout ratio is presently 20.61%.
About Danaher
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
